## Shu-Chen Kuo

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3954533/publications.pdf

Version: 2024-02-01

136950 197818 3,408 138 32 49 h-index citations g-index papers 139 139 139 5461 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The prediction values of carbapenemase detection methods and carbapenem susceptibility testing for clinical outcomes of patients with Acinetobacter bacteremia under carbapenem treatment. Journal of Microbiology, Immunology and Infection, 2022, 55, 257-265.	3.1	2
2	Early and Standard Urinary Catheter Removal After Gynecological Surgery for Benign Lesions: A Quasi-Experimental Study. Clinical Nursing Research, 2022, 31, 489-496.	1.6	4
3	<i>ln vitro</i> and <i>inÂvivo</i> comparison of eravacycline- and tigecycline-based combination therapies for tigecycline-resistant <i>Acinetobacter baumannii</i> Journal of Chemotherapy, 2022, 34, 166-172.	1.5	2
4	Pregnant women with COVID-19. Taiwanese Journal of Obstetrics and Gynecology, 2022, 61, 197-198.	1.3	4
5	Emergence of mcr-1, mcr-3 and mcr-8 in clinical Klebsiella pneumoniae isolates in Taiwan. Clinical Microbiology and Infection, 2021, 27, 305-307.	6.0	10
6	<i>ln vitro</i> and <i>in vivo</i> activities of imipenem combined with BLI-489 against class D β-lactamase-producing <i>Acinetobacter baumannii</i> Journal of Antimicrobial Chemotherapy, 2021, 76, 451-459.	3.0	3
7	Susceptibility of <i>Elizabethkingia</i> spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods. Journal of Antimicrobial Chemotherapy, 2021, 76, 653-658.	3.0	16
8	Nonpolio Enterovirus Activity during the COVID-19 Pandemic, Taiwan, 2020. Emerging Infectious Diseases, 2021, 27, 306-308.	4.3	12
9	Clinical and molecular characterization of Acinetobacter seifertii in Taiwan. Journal of Antimicrobial Chemotherapy, 2021, 76, 312-321.	3.0	8
10	Ser253Leu substitution in PmrB contributes to colistin resistance in clinical Acinetobacter nosocomialis. Emerging Microbes and Infections, 2021, 10, 1873-1880.	6.5	1
11	<i>In vitro</i> activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. Journal of Antimicrobial Chemotherapy, 2021, 76, 2071-2078.	3.0	20
12	Antimicrobial Resistance Mechanisms and Virulence of Colistin- and Carbapenem-Resistant Acinetobacter baumannii Isolated from a Teaching Hospital in Taiwan. Microorganisms, 2021, 9, 1295.	3.6	12
13	Mobile resistomes of human pathogens in swine wastewater treatment plants. Journal of Microbiology, Immunology and Infection, 2021, 54, 752-754.	3.1	O
14	Increased mcr-1 in pathogenic Escherichia coli from diseased swine, Taiwan. Journal of Microbiology, Immunology and Infection, 2020, 53, 751-756.	3.1	18
15	Policy-driven revolution of prescription record in outpatient use of fluoroquinolones. Journal of Microbiology, Immunology and Infection, 2020, 53, 133-140.	3.1	8
16	A Supramolecular Trap to Increase the Antibacterial Activity of Colistin. Angewandte Chemie - International Edition, 2020, 59, 1430-1434.	13.8	12
17	Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016. International Journal of Antimicrobial Agents, 2020, 55, 105883.	2.5	23
18	Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia. Antimicrobial Resistance and Infection Control, 2020, 9, 160.	4.1	5

#	Article	IF	CITATIONS
19	Clinical and economic impact of intensive care unit-acquired bloodstream infections in Taiwan: a nationwide population-based retrospective cohort study. BMJ Open, 2020, 10, e037484.	1.9	5
20	Collateral Benefit of COVID-19 Control Measures on Influenza Activity, Taiwan. Emerging Infectious Diseases, 2020, 26, 1928-1930.	4.3	106
21	Frontispiece: A Supramolecular Trap to Increase the Antibacterial Activity of Colistin. Angewandte Chemie - International Edition, 2020, 59, .	13.8	0
22	Frontispiz: A Supramolecular Trap to Increase the Antibacterial Activity of Colistin. Angewandte Chemie, 2020, 132, .	2.0	0
23	A Supramolecular Trap to Increase the Antibacterial Activity of Colistin. Angewandte Chemie, 2020, 132, 1446-1450.	2.0	2
24	Is Polymicrobial Bacteremia an Independent Risk Factor for Mortality in Acinetobacter baumannii Bacteremia?. Journal of Clinical Medicine, 2020, 9, 153.	2.4	19
25	Multicentre study of risk factors for mortality in patients with Acinetobacter bacteraemia receiving colistin treatment. International Journal of Antimicrobial Agents, 2020, 55, 105956.	2.5	6
26	Confronting Tigecycline-Resistant Acinetobacter baumannii via Immunization Against Conserved Resistance Determinants. Frontiers in Microbiology, 2020, 11, 536.	3.5	7
27	Plasmid- and chromosome-located mcr-3 in mcr-1-positive Escherichia coli in Taiwan. International Journal of Antimicrobial Agents, 2020, 56, 105996.	2.5	1
28	Bacterial membrane vesicles from <i>Acinetobacter baumannii</i> induced by ceftazidime are more virulent than those induced by imipenem. Virulence, 2020, 11, 145-158.	4.4	8
29	Visiting in disguise: Analysis of inpatient companions in the time of COVID-19. Journal of the Chinese Medical Association, 2020, 83, 1111-1116.	1.4	3
30	A multicenter study on clinical characteristics of Acinetobacter bacteremia in patients with liver cirrhosis. Journal of Microbiology, Immunology and Infection, 2019, 52, 956-965.	3.1	5
31	Influenza vaccination and secondary prevention of cardiovascular disease among Taiwanese elders—A propensity score-matched follow-up study. PLoS ONE, 2019, 14, e0219172.	2.5	25
32	Completing Circular Bacterial Genomes With Assembly Complexity by Using a Sampling Strategy From a Single MinION Run With Barcoding. Frontiers in Microbiology, 2019, 10, 2068.	3.5	21
33	Molecular Epidemiology of Emerging Carbapenem Resistance in <i>Acinetobacter nosocomialis</i> and <i>Acinetobacter pittii</i> in Taiwan, 2010 to 2014. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	23
34	Effect of diabetes mellitus on risk of latent TB infection in a high TB incidence area: a community-based study in Taiwan. BMJ Open, 2019, 9, e029948.	1.9	20
35	Use of lipid-lowering agents is not associated with improved outcomes for tuberculosis patients on standard-course therapy: A population-based cohort study. PLoS ONE, 2019, 14, e0210479.	2.5	10
36	Implementation and Effectiveness of a Bar Code–Based Transfusion Management System for Transfusion Safety in a Tertiary Hospital: Retrospective Quality Improvement Study. JMIR Medical Informatics, 2019, 7, e14192.	2.6	3

3

#	Article	IF	Citations
37	Molecular Epidemiology of Emerging <i>bla</i> <sub>OXA-23-Like</sub> - and <i>bla</i> <sub>OXA-24-Like</sub> -Carrying Acinetobacter baumannii in Taiwan. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	15
38	Subnanometer Gold Clusters Adhere to Lipid A for Protection against Endotoxin-Induced Sepsis. Nano Letters, 2018, 18, 2864-2869.	9.1	33
39	Risk of Mortality of Catheter-Related Bloodstream Infections Caused by <i>Acinetobacter</i> Species. Journal of Intensive Care Medicine, 2018, 33, 361-369.	2.8	5
40	Community-acquired bloodstream infections caused by Acinetobacter baumannii: AÂmatched case–control study. Journal of Microbiology, Immunology and Infection, 2018, 51, 629-635.	3.1	28
41	Impact of reduced tigecycline susceptibility on clinical outcomes of Acinetobacter bacteremia. Journal of Microbiology, Immunology and Infection, 2018, 51, 148-152.	3.1	2
42	Effectiveness of coffee for postoperative ileus in patients following abdominal surgery: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports, 2018, 16, 2072-2079.	1.7	2
43	Colistin nanoparticle assembly by coacervate complexation with polyanionic peptides for treating drug-resistant gram-negative bacteria. Acta Biomaterialia, 2018, 82, 133-142.	8.3	36
44	Adding a C-terminal Cysteine (CTC) Can Enhance the Bactericidal Activity of Three Different Antimicrobial Peptides. Frontiers in Microbiology, 2018, 9, 1440.	3.5	19
45	Biofilm formation is not associated with worse outcome in Acinetobacter baumannii bacteraemic pneumonia. Scientific Reports, 2018, 8, 7289.	3.3	30
46	Association between influenza vaccination and the reduced risk of acute kidney injury among older people: A nested case-control study. European Journal of Internal Medicine, 2018, 54, 65-69.	2,2	7
47	Comparison between bacteremia caused by Acinetobacter pittii and Acinetobacter nosocomialis. Journal of Microbiology, Immunology and Infection, 2017, 50, 62-67.	3.1	21
48	Genetic diversity of the Mycobacterium tuberculosis East African–Indian family in three tropical Asian countries. Journal of Microbiology, Immunology and Infection, 2017, 50, 886-892.	3.1	11
49	An Outbreak of <i>Ralstonia pickettii</i> Bloodstream Infection Associated with an Intrinsically Contaminated Normal Saline Solution. Infection Control and Hospital Epidemiology, 2017, 38, 444-448.	1.8	27
50	Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure. Heart, 2017, 103, 414-420.	2.9	17
51	Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 262-271.	4.5	22
52	A medically relevant capsular polysaccharide in Acinetobacter baumannii is a potential vaccine candidate. Vaccine, 2017, 35, 1440-1447.	3.8	36
53	Antibiotic restriction policy paradoxically increased private drug consumptions outside Taiwan's National Health Insurance. Journal of Antimicrobial Chemotherapy, 2017, 72, 1544-1545.	3.0	8
54	The impact of chronic hepatitis B infection on major adverse cardiovascular events and all-cause mortality in patients with diabetes: a nationwide population-based study from Taiwan. BMJ Open, 2017, 7, e016179.	1.9	14

#	Article	IF	CITATIONS
55	Clinical Antibiotic-resistant Acinetobacter baumannii Strains with Higher Susceptibility to Environmental Phages than Antibiotic-sensitive Strains. Scientific Reports, 2017, 7, 6319.	3.3	45
56	Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients. American Heart Journal, 2017, 193, 1-7.	2.7	39
57	Verapamil Use Is Associated With Reduction of Newly Diagnosed Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2604-2610.	3.6	32
58	Sensitivity and specificity of Matrix-Associated Laser Desorption/Ionization – Time of Flight Mass Spectrometry (MALDI-TOF MS) in discrimination at species level for Acinetobacter bacteremia. Journal of Microbiological Methods, 2017, 140, 58-60.	1.6	4
59	Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	9
60	Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	4
61	Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke. Journal of Hypertension, 2016, 34, 567-575.	0.5	7
62	Long-Term Outcomes in Critically Ill Septic Patients Who Survived Cardiopulmonary Resuscitation*. Critical Care Medicine, 2016, 44, 1067-1074.	0.9	15
63	Association between previous history of gout attack and risk of deep vein thrombosis - a nationwide population-based cohort study. Scientific Reports, 2016, 6, 26541.	3.3	18
64	Rapid hypoglycemia onset associated with antimicrobial use in patients with diabetes: A nationwide population-based case-crossover study. European Journal of Internal Medicine, 2016, 34, e14-e15.	2.2	2
65	Association Between Use of Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Kidney Injury: A Nested Case-Control Study. Mayo Clinic Proceedings, 2016, 91, 867-872.	3.0	12
66	Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm Architecture. Antimicrobial Agents and Chemotherapy, 2016, 60, 4670-4676.	3.2	28
67	Colistin resistance gene <i>mcr</i> -1 in <i>Escherichia coli</i> isolates from humans and retail meats, Taiwan. Journal of Antimicrobial Chemotherapy, 2016, 71, 2327-2329.	3.0	76
68	<i>In Vivo</i> and <i>In Vitro</i> Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2016, 60, 4047-4054.	3.2	36
69	<i>In vitro</i> activity of SecA inhibitors in combination with carbapenems against carbapenem-hydrolysing class D β-lactamase-producing <i>Acinetobacter baumannii</i> . Journal of Antimicrobial Chemotherapy, 2016, 71, 3441-3448.	3.0	6
70	Long-Term Mortality and Major Adverse Cardiovascular Events in Sepsis Survivors. A Nationwide Population-based Study. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 209-217.	5.6	149
71	Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy. Cmaj, 2016, 188, E148-E157.	2.0	11
72	Diabetes mellitus is associated with acquisition and increased mortality in HIV-uninfected patients with cryptococcosis: A population-based study. Journal of Infection, 2016, 72, 608-614.	3.3	35

#	Article	IF	CITATIONS
73	Adverse Effects of Oral Nonselective and cyclooxygenase-2-Selective NSAIDs on Hospitalization for Acute Kidney Injury. Medicine (United States), 2016, 95, e2645.	1.0	39
74	Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation. Circulation, 2016, 133, 265-272.	1.6	69
75	Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study. Journal of the American Medical Directors Association, 2016, 17, 59-64.	2.5	12
76	Risk factors and clinical outcome ofÂsulbactam nonsusceptibility inÂmonomicrobial Acinetobacter nosocomialis bacteremia. Journal of Microbiology, Immunology and Infection, 2016, 49, 371-377.	3.1	1
77	Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia. PLoS ONE, 2016, 11, e0163271.	2.5	8
78	Association between Use of Oral Anti-Diabetic Drugs and the Risk of Sepsis: A Nested Case-Control Study. Scientific Reports, 2015, 5, 15260.	3.3	29
79	Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Annals of Internal Medicine, 2015, 163, 663-672.	3.9	81
80	Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma. BMC Cancer, 2015, 15, 704.	2.6	14
81	Molecular Epidemiology of Tuberculosis in Kaohsiung City Located at Southern Taiwan, 2000-2008. PLoS ONE, 2015, 10, e0117061.	2.5	11
82	Association of Hypoglycemia With Incident Chronic Kidney Disease in Patients With Type 2 Diabetes. Medicine (United States), 2015, 94, e771.	1.0	15
83	Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients. Medicine (United) Tj ETQq1 1 (	0.784614	rgBI2/Overlac
84	A retrospective study of the incidence, clinical characteristics, identification, and antimicrobial susceptibility of bacteremic isolates of Acinetobacter ursingii. BMC Infectious Diseases, 2015, 15, 400.	2.9	16
85	Molecular epidemiology of carbapenem non-susceptible Acinetobacter nosocomialis in a medical center in Taiwan. Infection, Genetics and Evolution, 2015, 31, 305-311.	2.3	9
86	Identification of novel vaccine candidates against <i>Acinetobacter baumannii</i> vaccinology. Human Vaccines and Immunotherapeutics, 2015, 11, 1065-1073.	3.3	86
87	Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii. Frontiers in Microbiology, 2015, 6, 231.	3.5	34
88	Effective transfer of a 47 kb NDM-1-positive plasmid among <i>Acinetobacter</i> species. Journal of Antimicrobial Chemotherapy, 2015, 70, 2734-2738.	3.0	24
89	Efficacy of Tigecycline for Secondary Acinetobacter Bacteremia and Factors Associated with Treatment Failure. Antimicrobial Agents and Chemotherapy, 2015, 59, 3637-3640.	3.2	17
90	Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study. Intensive Care Medicine, 2015, 41, 806-813.	8.2	57

#	Article	IF	CITATIONS
91	Acinetobacter baumannii Extracellular OXA-58 Is Primarily and Selectively Released via Outer Membrane Vesicles after Sec-Dependent Periplasmic Translocation. Antimicrobial Agents and Chemotherapy, 2015, 59, 7346-7354.	3.2	41
92	Risk factors of community-onset urinary tract infections caused by plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae. Journal of Microbiology, Immunology and Infection, 2015, 48, 269-275.	3.1	25
93	Epidemiology and risk factors of community-onset urinary tract infection caused by extended-spectrum Î <sup>2</sup> -lactamase-producing Enterobacteriaceae in a medical center in Taiwan: A prospective cohort study. Journal of Microbiology, Immunology and Infection, 2015, 48, 168-174.	3.1	29
94	Evolution of carbapenem resistance in Acinetobacter baumannii: An 18-year longitudinal study from a medical center inÂnorthern Taiwan. Journal of Microbiology, Immunology and Infection, 2015, 48, 57-64.	3.1	13
95	The Pattern of Cytokine Production In Vitro Induced by Ancient and Modern Beijing Mycobacterium tuberculosis Strains. PLoS ONE, 2014, 9, e94296.	2.5	33
96	Distinct Modes of Transmission of Tuberculosis in Aboriginal and Non-Aboriginal Populations in Taiwan. PLoS ONE, 2014, 9, e112633.	2.5	3
97	Association Between Recent Use of Proton Pump Inhibitors and Nontyphoid Salmonellosis: A Nested Case-Control Study. Clinical Infectious Diseases, 2014, 59, 1554-1558.	5.8	38
98	Levofloxacin-Resistant <i>Haemophilus influenzae</i> , Taiwan, 2004–2010. Emerging Infectious Diseases, 2014, 20, 1386-1390.	4.3	41
99	Association of Postdischarge Rehabilitation with Mortality in Intensive Care Unit Survivors of Sepsis. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1003-1011.	5.6	97
100	Reply to Farioli and Kriebel. Clinical Infectious Diseases, 2014, 58, 1490-1490.	5.8	0
101	The impact of dialysis therapy on older patients with advanced chronic kidney disease: a nationwide population-based study. BMC Medicine, 2014, 12, 169.	5.5	34
102	Association Between Recent Use of Fluoroquinolones and Rhegmatogenous Retinal Detachment: A Population-Based Cohort Study. Clinical Infectious Diseases, 2014, 58, 197-203.	5.8	36
103	Risk of tuberculosis among healthcare workers in an intermediate-burden country: A nationwide population study. Journal of Infection, 2014, 69, 525-532.	3.3	26
104	Long-Term Clinical Outcome of Major Adverse Cardiac Events in Survivors of Infective Endocarditis. Circulation, 2014, 130, 1684-1691.	1.6	96
105	Rapid identification of Acinetobacter baumannii, Acinetobacter nosocomialis and Acinetobacter pittii with a multiplex PCR assay. Journal of Medical Microbiology, 2014, 63, 1154-1159.	1.8	50
106	Effect of the use of low and high potency statins and sepsis outcomes. Intensive Care Medicine, 2014, 40, 1509-1517.	8.2	39
107	Sheltering Effect and Indirect Pathogenesis of Carbapenem-Resistant Acinetobacter baumannii in Polymicrobial Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 3983-3990.	3.2	35
108	Risk factors for imipenem-nonsusceptible Acinetobacter nosocomialis bloodstream infection. Journal of Microbiology, Immunology and Infection, 2014, 47, 311-317.	3.1	17

#	Article	IF	CITATIONS
109	Molecular epidemiology of Mycobacterium tuberculosis in aboriginal peoples of Taiwan, 2006–2011. Journal of Infection, 2014, 68, 332-337.	3.3	14
110	Dissemination of imipenem-resistant Acinetobacter baumannii with new plasmid-borne bla OXA-72 in Taiwan. BMC Infectious Diseases, 2013, 13, 319.	2.9	32
111	Comparison between bacteremia caused by carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis. BMC Infectious Diseases, 2013, 13, 311.	2.9	24
112	Acinetobacter baumannii nosocomial pneumonia: is the outcome more favorable in non-ventilated than ventilated patients?. BMC Infectious Diseases, 2013, 13, 142.	2.9	24
113	Associated clinical characteristics of patients with candidemia among different Candida species. Journal of Microbiology, Immunology and Infection, 2013, 46, 463-468.	3.1	20
114	Incidence and outcome of newly-diagnosed tuberculosis in schizophrenics: a 12-year, nationwide, retrospective longitudinal study. BMC Infectious Diseases, 2013, 13, 351.	2.9	18
115	Dissemination of multidrug-resistant Acinetobacter baumannii carrying BlaOxA-23 from hospitals in central Taiwan. Journal of Microbiology, Immunology and Infection, 2013, 46, 419-424.	3.1	35
116	Comparison between patients under hemodialysis with community-onset bacteremia caused by community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus strains. Journal of Microbiology, Immunology and Infection, 2013, 46, 96-103.	3.1	16
117	Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia. Clinical Microbiology and Infection, 2013, 19, 634-639.	6.0	20
118	Impact of Appropriate Antimicrobial Therapy on Mortality Associated With Acinetobacter baumannii Bacteremia: Relation to Severity of Infection. Clinical Infectious Diseases, 2012, 55, 209-215.	5.8	92
119	Emergence of Carbapenem-Resistant Non-baumannii Species of Acinetobacter Harboring ablaOXA-51-Like Gene That Is Intrinsic to A. baumannii. Antimicrobial Agents and Chemotherapy, 2012, 56, 1124-1127.	3.2	79
120	Clinical characteristics and prognostic factors of Acinetobacter nosocomialis bacteraemia in patients with solid tumours. Clinical Microbiology and Infection, 2012, 18, E373-E376.	6.0	7
121	Treatment of community-onset methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: A hospital-based study. Archives of Gerontology and Geriatrics, 2012, 55, 152-156.	3.0	4
122	Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acinetobacter genomic species 13TU. Journal of Microbiology, Immunology and Infection, 2012, 45, 108-112.	3.1	23
123	Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: Nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. BMC Infectious Diseases, 2012, 12, 200.	2.9	85
124	Comparison of microbiological and clinical characteristics based on SCCmec typing in patients with community-onset meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia. International Journal of Antimicrobial Agents, 2012, 39, 22-26.	2.5	13
125	Clinical characteristics of Acinetobacter baumannii complex bacteremia in patients receiving total parenteral nutrition. Journal of the Chinese Medical Association, 2012, 75, 102-108.	1.4	2
126	Risk factors and clinical outcomes of patients with carbapenem-resistant AcinetobacterÂbaumannii bacteremia. Journal of Microbiology, Immunology and Infection, 2012, 45, 356-362.	3.1	75

#	Article	IF	CITATIONS
127	Genetic Diversity of the Mycobacterium tuberculosis Beijing Family Based on SNP and VNTR Typing Profiles in Asian Countries. PLoS ONE, 2012, 7, e39792.	2.5	30
128	Clonal Expansion of Both Modern and Ancient Genotypes of Mycobacterium tuberculosis in Southern Taiwan. PLoS ONE, 2012, 7, e43018.	2.5	20
129	Polymerase chain reaction assay for the detection of Acinetobacter baumannii in endotracheal aspirates from patients in the intensive care unit. Journal of Microbiology, Immunology and Infection, 2011, 44, 106-110.	3.1	32
130	Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients. Journal of Microbiology, Immunology and Infection, 2011, 44, 45-51.	3.1	21
131	Predictors of mortality in surgical patients with Acinetobacter baumannii bacteremia. Journal of Microbiology, Immunology and Infection, 2011, 44, 209-214.	3.1	7
132	Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated Acinetobacter baumannii complex in a medical center in Taiwan, 1997–2007. Journal of Microbiology, Immunology and Infection, 2011, 44, 358-363.	3.1	18
133	Prediction of Patient Outcome from Acinetobacter baumannii Bacteremia with Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II Scores. Internal Medicine, 2011, 50, 871-877.	0.7	31
134	Bacteremia Due to <i>Acinetobacter</i> Genomic Species 10. Journal of Clinical Microbiology, 2010, 48, 586-590.	3.9	13
135	Contribution of a Plasmid-Borne <i>bla</i> <sub>OXA-58</sub> Gene with Its Hybrid Promoter Provided by IS <i>1006</i> and an IS <i>Aba3</i> -Like Element to β-Lactam Resistance in <i>Acinetobacter</i> Genomic Species 13TU. Antimicrobial Agents and Chemotherapy, 2010, 54, 3107-3112.	3.2	47
136	Emergence and Distribution of Plasmids Bearing the $\langle i \rangle$ bla $\langle  i \rangle \langle sub \rangle$ OXA-51 $\langle  sub \rangle \rangle$ -Like Gene with an Upstream IS $\langle i \rangle$ Aba1 $\langle  i \rangle$ in Carbapenem-Resistant $\langle i \rangle$ Acinetobacter baumannii $\langle  i \rangle$ Isolates in Taiwan. Antimicrobial Agents and Chemotherapy, 2010, 54, 4575-4581.	3.2	125
137	Primary Small Cell Carcinoma of the Stomach Successfully Treated With Cisplatin and Etoposide. Journal of the Chinese Medical Association, 2009, 72, 598-602.	1.4	8
138	Deterioration of the liver biochemistry due to reactivation of chronic hepatitis B during etanercept treatment for rheumatoid arthritis. BMJ Case Reports, 2009, 2009, bcr0920080873-bcr0920080873.	0.5	1